REVIEW MODIFIKASI KELARUTAN PIROKSIKAM

Authors

  • Ayudyah Islami Departemen Farmasetika dan Teknologi Farmasi, Universitas Padjadjaran, Jatinangor
  • Iyan Sopyan Departemen Farmasetika dan Teknologi Farmasi, Universitas Padjadjaran, Jatinangor
  • Dolih Gozali Departemen Farmasetika dan Teknologi Farmasi, Universitas Padjadjaran, Jatinangor
  • Hairunnisa Hairunnisa Departemen Farmasetika dan Teknologi Farmasi, Universitas Padjadjaran, Jatinangor

DOI:

https://doi.org/10.52434/jfb.v11i1.697

Abstract

Piroksikam, merupakan golongan NSAID, digunakan pada rheumatoid arthritis dan osteoarthritis untuk mengurangi rasa sakit. Waktu paruh piroksikam adalah 24 hingga 48 jam. Berdasarkan Biopharmaceutical Classification System (BCS), piroksikam termasuk dalam kelas II yang memiliki kelarutan air rendah, titik lelehnya 190-200oC, nilai log P 3,06, nilai pKa 6,3, dan Vd 0,14 L / kg. Kelarutan piroksikam ditentukan oleh tingkat ionisasi. Ketika pH diperoleh melalui pKa, terjadi peningkatan kelarutan dan disolusi. Oleh karena itu, modifikasi piroksikam dengan dispersi padat dan teknik kristristalisasi diharapkan dapat meningkatkan kelarutan piroksikam dan memfasilitasi formulasi piroksikam menjadi bentuk sediaan yang efektif. Namun, setiap modifikasi memiliki kelebihan dan kekurangan masing-masing yang dapat dipertimbangkan ketika merancang piroksikam menjadi bentuk sediaan. Kata kunci: kokristal, dispersi padat, piroksikam, kelarutan, disolusi

References

Shohin IE, Kulinich JI, Ramenskaya G V., Abrahamsson B, Kopp S, Langguth P, et al. Biowaiver monographs for immediate release solid oral dosage forms: Piroxicam. J Pharm Sci. 2014;103(2):367–77.

Banchero M, Manna L. Investigation of the piroxicam/hydroxypropyl-β-cyclodextrin inclusion complexation by means of a supercritical solvent in the presence of auxiliary agents. J Supercrit Fluids [Internet]. 2011;57(3):259–66. Available from: http://dx.doi.org/10.1016/j.supflu.2011.04.006

Gwak HS, Choi JS, Choi HK. Enhanced bioavailability of piroxicam via salt formation with ethanolamines. Int J Pharm. 2005;297(1–2):156–61.

Paaver U, Lust A, Mirza S, Rantanen J, Veski P, Heinämäki J, et al. Insight into the solubility and dissolution behavior of piroxicam anhydrate and monohydrate forms. Int J Pharm [Internet]. 2012;431(1–2):111–9. Available from: http://dx.doi.org/10.1016/j.ijpharm.2012.04.042

VreÄer F, Vrbinc M, Meden A. Characterization of piroxicam crystal modifications. Int J Pharm. 2003;256(1–2):3–15.

Nyström M, Roine J, Murtomaa M, Mohan Sankaran R, Santos HA, Salonen J. Solid state transformations in consequence of electrospraying - A novel polymorphic form of piroxicam. Eur J Pharm Biopharm. 2015;89(December):182–9.

Rasetti-Escargueil C, Grangé V. Pharmacokinetic profiles of two tablet formulations of piroxicam. Int J Pharm. 2005;295(1–2):129–34.

Kavanagh ON, Croker DM, Walker GM, Zaworotko MJ. Pharmaceutical cocrystals: from serendipity to design to application. Drug Discov Today [Internet]. 2018; Available from: https://linkinghub.elsevier.com/retrieve/pii/S1359644618303751

Sridhar I, Doshi A, Joshi B, Wankhede V, Doshi J. Solid Dispersions: an Approach to Enhance Solubility of poorly Water Soluble Drug. J Sci Innov Res. 2013;2(3):685–94.

Quirk RA, France RM, Shakesheff KM, Howdle SM. Supercritical fluid technologies and tissue engineering scaffolds. Curr Opin Solid State Mater Sci. 2004;8(3–4):313–21.

El-Badry M, Fathy M. Properties of solid dispersion of piroxicam in Pluronic F-98. J Drug Deliv Sci Technol. 2004;14(3):199–205.

Cerreia Vioglio P, Chierotti MR, Gobetto R. Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges. Adv Drug Deliv Rev [Internet]. 2017;117:86–110. Available from: https://doi.org/10.1016/j.addr.2017.07.001

Douroumis D, Ross SA, Nokhodchi A. Advanced methodologies for cocrystal synthesis. Adv Drug Deliv Rev [Internet]. 2017;117:178–95. Available from: http://dx.doi.org/10.1016/j.addr.2017.07.008

Arunan E, Desiraju GR, Klein RA, Sadlej J, Scheiner S, Alkorta I, et al. Definition of the hydrogen bond (IUPAC Recommendations 2011). Pure Appl Chem. 2011;83(8):1637–41.

Bavishi DD, Borkhataria CH. Spring and parachute: How cocrystals enhance solubility. Prog Cryst Growth Charact Mater [Internet]. 2016;62(3):1–8. Available from: http://dx.doi.org/10.1016/j.pcrysgrow.2016.07.001

Mirza S, Miroshnyk I, Habib MJ, Brausch JF, Hussain MD. Enhanced dissolution and oral bioavailability of piroxicam formulations: Modulating effect of phospholipids. Pharmaceutics. 2010;2(4):339–50.

Manin AN, Voronin AP, Drozd K V, Manin NG, Bauer-Brandl A, Perlovich GL. Cocrystal screening of hydroxybenzamides with benzoic acid derivatives: a comparative study of thermal and solution-based methods. Eur J Pharm Sci. 2014;65:56–64.

Fucke K, Myz SA, Shakhtshneider TP, Boldyreva E V., Griesser UJ. How good are the crystallisation methods for co-crystals? A comparative study of piroxicam. New J Chem. 2012;36(10):1969–77.

Aakeröy CB, Rajbanshi A, Li ZJ, Desper J. Mapping out the synthetic landscape for re-crystallization, co-crystallization and salt formation. CrystEngComm. 2010;12(12):4231–9.

Okabe N, Suga T. 3-(p-Hydroxyphenyl) propionic Acid. Acta Crystallogr Sect C Cryst Struct Commun. 1995;51(7):1324–5.

Rodrigues M, Baptista B, Loper JA, Sarraguca MC. Pharmaceutical cocrystallization techniques. Advances and challenges. Int J Pharm. 2018;574:404–20.

Iveson SM, Litster JD, Hapgood K, Ennis BJ. Nucleation, growth and breakage phenomena in agitated wet granulation processes: a review. Powder Technol. 2001;117(1–2):3–39.

Vehring R, Foss WR, Lechuga-Ballesteros D. Particle formation in spray drying. J Aerosol Sci. 2007;38(7):728–46.

Grossjohann C, Serrano DR, Paluch KJ, O’Connell P, Vella-Zarb L, Manesiotis P, et al. Polymorphism in sulfadimidine/4-aminosalicylic acid cocrystals: solid-state characterization and physicochemical properties. J Pharm Sci. 2015;104(4):1385–98.

Patil SP, Modi SR, Bansal AK. Generation of 1: 1 carbamazepine: nicotinamide cocrystals by spray drying. Eur J Pharm Sci. 2014;62:251–7.

Wang I-C, Lee M-J, Sim S-J, Kim W-S, Chun N-H, Choi GJ. Anti-solvent co-crystallization of carbamazepine and saccharin. Int J Pharm. 2013;450(1–2):311–22.

Lange L, Heisel S, Sadowski G. Predicting the solubility of pharmaceutical cocrystals in solvent/anti-solvent mixtures. Molecules. 2016;21(5):593.

Padrela L, Rodrigues MA, Velaga SP, Matos HA, de Azevedo EG. Formation of indomethacin–saccharin cocrystals using supercritical fluid technology. Eur J Pharm Sci. 2009;38(1):9–17.

Eddleston MD, Patel B, Day GM, Jones W. Cocrystallization by freeze-drying: preparation of novel multicomponent crystal forms. Cryst Growth Des. 2013;13(10):4599–606.

Emami S, Adibkia K, Barzegar-Jalali M, Siahi-Shadbad M. Piroxicam cocrystals with phenolic coformers: preparation, characterization, and dissolution properties. Pharm Dev Technol [Internet]. 2018;0(0):1–12. Available from: http://dx.doi.org/10.1080/10837450.2018.1455210

Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst growth Des. 2009;9(6):2950–67.

Downloads

Published

2020-02-07

Issue

Vol. 11 No. 1 (2020): Jurnal Ilmiah Farmako Bahari

Section

Research Article

License

or all articles published in Jurnal Ilmiah Farmako Bahari, the copyright is retained by the journal. Articles are published under the terms of Creative Commons Attribution-ShareAlike 4.0 International License (CC-BY-SA 4.0) .

For Authors:

  • Any article on the copyright is retained by the author(s).
  • The author grants the journal, right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share work with an acknowledgment of the work authors and initial publications in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of published articles of work (eg, post-institutional repository) or publish it in a book, with acknowledgment of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their websites) prior to and during the submission process, as can lead to productive exchanges, as well as earlier and greater citation of published work.
  • The article and any associated published material is distributed under the Creative Commons Attribution-ShareAlike 4.0 International License